ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.

MLA

Airiau, Kelly, et al. “ABT-737 Increases Tyrosine Kinase Inhibitor-Induced Apoptosis in Chronic Myeloid Leukemia Cells through XIAP Downregulation and Sensitizes CD34(+) CD38(-) Population to Imatinib.” Experimental Hematology, vol. 40, no. 5, May 2012, p. 367. EBSCOhost, https://doi.org/10.1016/j.exphem.2012.01.004.

APA

Airiau, K., Mahon, F.-X., Josselin, M., Jeanneteau, M., Turcq, B., & Belloc, F. (2012). ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib. Experimental Hematology, 40(5), 367. https://doi.org/10.1016/j.exphem.2012.01.004

Chicago

Airiau, Kelly, François-Xavier Mahon, Marina Josselin, Marie Jeanneteau, Beatrice Turcq, and Francis Belloc. 2012. “ABT-737 Increases Tyrosine Kinase Inhibitor-Induced Apoptosis in Chronic Myeloid Leukemia Cells through XIAP Downregulation and Sensitizes CD34(+) CD38(-) Population to Imatinib.” Experimental Hematology 40 (5): 367. doi:10.1016/j.exphem.2012.01.004.